A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer's disease.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2020.112766DOI Listing

Publication Analysis

Top Keywords

structure-activity relationship
4
relationship study
4
study tryptophan-based
4
tryptophan-based butyrylcholinesterase
4
butyrylcholinesterase inhibitors
4
inhibitors series
4
series tryptophan-based
4
tryptophan-based selective
4
selective nanomolar
4
nanomolar butyrylcholinesterase
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!